Cooley represented the former board of directors of Sequenom in a nearly seven-year-long securities class action brought by former investors in the company. In July 2016,...
You must be a Standard 1 Year member to access this content.
Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Davis Polk represented the underwriters, Cooley represented Arlo and its officers and directors, and Wilson Sonsini represented Netgear. In the California state and federal court securities...
You must be a Standard 1 Year member to access this content.
Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal. Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its...
You must be a Standard 1 Year member to access this content.
